Semaglutide Research for Heart Failure
An evidence-based overview of research examining Semaglutide in the context of heart failure. This page synthesizes findings from peer-reviewed literature.
Research Summary
Semaglutide has shown benefits in heart failure with preserved ejection fraction (HFpEF) in patients with obesity. The STEP-HFpEF trials demonstrated improved symptoms, physical function, and quality of life measures. The SELECT trial subanalysis of 4,286 patients with prevalent heart failure showed semaglutide improved cardiovascular outcomes (MACE HR 0.72), cardiovascular death (HR 0.76), and all-cause death (HR 0.81). Benefits were consistent across both HFrEF and HFpEF subtypes. For patients with obesity and heart failure, semaglutide may provide cardiovascular protection through weight loss, reduced inflammation, improved metabolic health, and potentially direct cardiac effects.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Heart Failure
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Semaglutide may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.